You are here:
26 July 2018 / deal

Acquisition of Takeda Chromo by Shanghai Pharmaceuticals Holding Co.

Loyens & Loeff advised Shanghai Pharmaceuticals on the acquisition of Takeda Chromo Beteiligungs AG.

Shanghai Pharmaceuticals Holding Co. (Hong Kong) announced the entering into a share purchase agreement with Takeda AG, a wholly-owned subsidiary of Takeda Japan (listed on the Tokyo Stock Exchange) to acquire 100% of the issued and outstanding share capital of Takeda Chromo Beteiligungs AG. Upon completion of the USD 144 million acquisition, Shanghai Pharmaceuticals will increase its direct and indirect shareholding in Techpool Bio-pharma Co., Ltd, a global leader in natural urine protein drugs, to approximately 67,14%. The acquisition is, among other conditions, still subject to approval by the China National Market Supervision Administration.

Loyens & Loeff advised Shanghai Pharmaceuticals Holding Co. as Swiss transaction counsel on this acquisition. The team was led by partner Marco Toni (Corporate / M&A, Switzerland) and consisted of Jana Bieli (Corporate / M&A, Switzerland) and Rebecca Kühne (Tax, Switzerland).

 



Employment tax

Loyens & Loeff advised Kongsberg Actuation Systems B.V.

L&L advised Kongsberg Actuation Systems B.V. on the issuance of EUR 275,000,000 5.000% Senior Secured Notes due 2025. read more

New FinTech License – What will be the Requirements?

The Swiss Federal Department of Finance initiated a consultation regarding a newly created FinTech license. What are the requirements? read more

EU mandatory disclosure rules: impact on Swiss businesses

The EU adopted directive introducing mandatory disclosure rules for certain corporate transactions with a cross-border dimension. What is the impact? read more